Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune ...
Recognition of telehealth as an effective strategy for delivering treatment for substance use disorder (SUD) has raised hopes for improving access to this treatment in settings with limited ...
Investor's Business Daily on MSN7h
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentAnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
ANSWER: Both RA and MCTD are rheumatologic diseases that affect many systems of the body. MCTD is often considered an overlap ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...
My husband, who is 71, has been having some short-term memory problems over the past two years. We recently saw his primary doctor, who asked him some questions ...
Intermittent fasting may benefit antioxidant and inflammatory markers in postmenopausal women with rheumatoid arthritis.
Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback